1. Accueil >
  2. ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and elderly patients with insomnia >
Nasdaq

ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and elderly patients with insomnia

28-07-2017


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Idorsia Pharmaceuticals Ltd. via GlobeNewswire

HUG#2123725